MedTrace Logo

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

NCT00038428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-07-25

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

TLK286

Sponsors & Collaborators

  • Telik

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038428 on ClinicalTrials.gov